EP0577544B1 — Novel cyclosporins having modifications at position 1
Assigned to Novartis AG · Expires 1996-12-18 · 29y expired
What this patent protects
Cyclosporins wherein the residue at the 1-position has the formula I <CHEM> in which -x-y- is -CH=CH-(trans) or -CH2-CH2-, X is 0 or S and R is hydrogen, optionally halo or hydroxy substituted-C1-3-alkyl, -alkoxy or -alkylthio, or amino or mono- or di-(C1-2alkyl)-amino, u…
USPTO Abstract
Cyclosporins wherein the residue at the 1-position has the formula I <CHEM> in which -x-y- is -CH=CH-(trans) or -CH2-CH2-, X is 0 or S and R is hydrogen, optionally halo or hydroxy substituted-C1-3-alkyl, -alkoxy or -alkylthio, or amino or mono- or di-(C1-2alkyl)-amino, useful as pharmaceuticals, preferentially for topical administration in particular for asthma therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.